Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05990543 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Combination of Nelmastobart and Capecitabine Therapy in Metastatic Colorectal Cancer

StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 8, 2025 (before its estimated December 1, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Start date changed from estimate of Aug 30, 2023 to Jan 29, 2024v2 Show 4 more changesShow less
    • Trial status: Not Yet Recruiting to Active, Not Recruiting
    • Study sites: 0 to 1
    • Primary completion date: Oct 1, 2025 to Dec 1, 2025
    • Study completion date: Mar 31, 2026 to Dec 31, 2026
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an open-label clinical trial aimed at evaluating the safety and efficacy of the combination treatment of nelmastobart with capecitabine in patients diagnosed with metastatic or recurrent colorectal cancer.
Trial Details
NCT Number NCT05990543
Lead Sponsor Korea University Anam Hospital
Conditions
(from sponsor)		 Recurrent or Metastatic Colorectal Cancer
Related terms Colorectal Neoplasms, Recurrence
Enrollment 59 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov